Does Daratumumab Cause Dilated Cardiomyopathy?
No, daratumumab does not cause dilated cardiomyopathy. Based on the FDA drug label and available clinical evidence, dilated cardiomyopathy is not listed as an adverse reaction associated with daratumumab therapy.
Evidence from FDA Drug Label
The comprehensive FDA safety data for daratumumab (DARZALEX) across multiple clinical trials involving thousands of patients does not identify dilated cardiomyopathy or heart failure as adverse reactions 11. The cardiac adverse events specifically documented include:
- Atrial fibrillation (listed as an adverse reaction in combination therapy)
- Hypertension (occurring in 10-33% of patients depending on regimen)
- Non-cardiac chest pain and musculoskeletal chest pain
Notably absent from the extensive adverse reaction tables and safety profiles is any mention of cardiomyopathy, heart failure, or reduced ejection fraction.
Cardioprotective Potential
Emerging research actually suggests daratumumab may have cardioprotective effects when combined with known cardiotoxic agents. A prospective study demonstrated that patients receiving daratumumab with carfilzomib (DaraKd) maintained preserved cardiac systolic function, while those receiving carfilzomib without daratumumab experienced significant deterioration in left ventricular ejection fraction and other cardiac function markers 2. This suggests daratumumab may attenuate, rather than cause, cardiac dysfunction.
Context: Known Cardiotoxic Cancer Therapies
For perspective, established cardiotoxic cancer therapies that DO cause dilated cardiomyopathy include 34:
- Anthracyclines (doxorubicin): 5-26% incidence depending on cumulative dose
- Trastuzumab: causes cardiac dysfunction in a subset of patients
- Proteasome inhibitors (carfilzomib): up to 25% risk of heart failure
- Radiotherapy: 4.9-fold increased risk of heart failure
Daratumumab, as a monoclonal antibody targeting CD38, operates through a completely different mechanism and lacks the direct cardiotoxic pathways of these agents.
Clinical Implications
You can reassure patients that dilated cardiomyopathy is not an expected adverse effect of daratumumab therapy. Standard cardiac monitoring protocols required for anthracyclines or proteasome inhibitors are not necessary specifically for daratumumab. However, if daratumumab is used in combination with known cardiotoxic agents (like carfilzomib), monitor for the cardiotoxicity of those agents, not daratumumab itself 11.
The most common adverse reactions to monitor with daratumumab include infusion-related reactions (48%), infections (particularly pneumonia), cytopenias, and hypertension 11.